RxDoctor Payments DataLook up a doctor →

Parthsarthi Patel, MD

Family Medicine · Newington, CTNPI 1629171756

Payments from drug & device makers

$17,835in general payments, 2019–2025

Across 1,165 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$3K
  • GSK$1K
  • Lilly USA, LLC$1000
  • Novo Nordisk$956
  • Boehringer Ingelheim$920
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$17,773100%
  • Education$620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)259$3,372
AstraZeneca132$2,944
GSK96$1,495
Lilly USA, LLC65$1,000
Novo Nordisk148$956
Boehringer Ingelheim47$920
Pfizer45$682
Bausch Health US, LLC34$546
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$495
Bayer29$449
Amgen(2 entities)23$426
Takeda Pharmaceuticals U.S.A., Inc.13$337
Optinose US, Inc.17$330
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$296
Exact Sciences14$235
Merck13$223
Phathom Pharmaceuticals, Inc.11$203
Indivior Inc.9$190
Abbott10$174
Ardelyx, Inc.8$173
Arbor Pharmaceuticals, Inc.12$159
Johnson & Johnson11$154
Corcept Therapeutics8$152
Esperion Therapeutics, Inc.11$151
Vanda Pharmaceuticals Inc.5$150
Hikma Pharmaceuticals USA9$146
Sanofi-aventis U.S. LLC6$126
Otsuka America Pharmaceutical, Inc.6$122
Kowa Pharmaceuticals America, Inc.8$121
Nestle Healthcare Nutrition Inc.7$103
Biohaven Pharmaceutical Holding Company Ltd.5$101
Gilead6$100
Melinta Therapeutics, LLC6$91
Evoke Pharma, Inc.5$77
Genentech USA, Inc.4$75
Eisai Inc.3$59
Scilex Pharmaceuticals Inc.3$48
Eyevance Pharmaceuticals LLC3$44
Novartis3$44
Orexo US, Inc.3$41
Biohaven Pharmaceuticals, Inc.2$38
Antares Pharma, Inc.2$30
Nabriva Therapeutics, PLC2$28
Metacel Pharmaceuticals LLC1$25
Adlon Therapeutics L.p.1$25
Zyla Life Sciences, Inc.1$22
Organon1$20
Aytu Biopharma, Inc.1$18
Vertical Pharmaceuticals, LLC1$17
Avanir Pharmaceuticals, Inc.1$17
Ironwood Pharmaceuticals, Inc1$15
Avion Pharmaceuticals1$15
Paratek Pharmaceuticals, Inc.1$15
Echosens North America, Inc.1$14
Philips North America LLC1$12
Shire North American Group Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,835 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$127,211
Medicare patients
425
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol167$234,902
OzempicSemaglutide70$138,380
TrulicityDulaglutide68$136,110
JardianceEmpagliflozin65$103,620
EliquisApixaban45$58,641
LinzessLinaclotide48$50,902
JanuviaSitagliptin Phosphate36$50,092
RybelsusSemaglutide13$37,474
TradjentaLinagliptin22$33,436
XareltoRivaroxaban25$29,533
JanumetSitagliptin Phos/Metformin Hcl20$26,183
Synjardy XrEmpagliflozin/Metformin Hcl14$25,356
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,792
ProliaDenosumab12$20,695
Soliqua 100-33Insulin Glargine/Lixisenatide20$16,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$2,944$244,548181 claims
Novo NordiskOzempic, Rybelsus$956$175,85483 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$920$162,412101 claims
Lilly USA, LLCTrulicity$1,000$136,11068 claims
MerckJanuvia, Janumet$223$76,27556 claims
PfizerEliquis$682$58,64145 claims
AbbVieLinzess, Synthroid$3,372$52,62260 claims
GSKTrelegy Ellipta, Breo Ellipta$1,495$32,51341 claims
Johnson & JohnsonXarelto$154$29,53325 claims
AmgenProlia$426$20,69512 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$126$16,29320 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$146$8,308101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Newington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →